Adaptive Stock Analysis

ADPT -  USA Stock  

USD 19.35  0.16  0.82%

The big decline in price over the last few months for Adaptive Biotechnologies could raise concerns from private investors as the firm it trading at a share price of 19.35 on very low momentum in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in December. However, diversifying your holdings with Adaptive Biotechnologies Corp or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.3. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Adaptive Biotechnologies partners.
Please continue to Trending Equities.

Adaptive Stock Analysis 

 
Refresh
The Adaptive Biotechnologies stock analysis report makes it easy to digest most publicly released information about Adaptive Biotechnologies and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Adaptive Stock analysis module also helps to analyze the Adaptive Biotechnologies price relationship with some important fundamental indicators such as market cap and management efficiency.

Adaptive Stock Analysis Notes

About 83.0% of the company shares are held by institutions such as insurance companies. The book value of Adaptive Biotechnologies was presently reported as 4.62. The company recorded a loss per share of 1.37. Adaptive Biotechnologies had not issued any dividends in recent years. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Adaptive Biotechnologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 622 people. For more info on Adaptive Biotechnologies Corp please contact Chad Robins at 855 466 8667 or go to https://www.adaptivebiotech.com.

Adaptive Biotechnologies Quarterly Cost of Revenue

14.19 MillionShare

Adaptive Biotechnologies Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Adaptive Biotechnologies' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Adaptive Biotechnologies Corp or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Adaptive Biotechnologies generated a negative expected return over the last 90 days
Adaptive Biotechnologies has high historical volatility and very poor performance
Adaptive Biotechnologies is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 146.6 M. Net Loss for the year was (190.42 M) with loss before overhead, payroll, taxes, and interest of (40.22 M).
Adaptive Biotechnologies Corp currently holds about 415.04 M in cash with (178.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94.
Adaptive Biotechnologies has a poor financial position based on the latest SEC disclosures
Over 83.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.nasdaq.com: Crown Castle Stock Moves -1.08 percent What You Should Know - Nasdaq

Adaptive Biotechnologies Upcoming and Recent Events

Earnings reports are used by Adaptive Biotechnologies to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Adaptive Biotechnologies previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of February 2022
Next Earnings Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Adaptive Largest EPS Surprises

Earnings surprises can significantly impact Adaptive Biotechnologies' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-02-26
2019-12-31-0.14-0.17-0.0321 
2021-02-24
2020-12-31-0.2938-0.33-0.036212 
2020-05-12
2020-03-31-0.212-0.25-0.03817 
View All Earnings Estimates

Adaptive Biotechnologies SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Adaptive Biotechnologies prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Adaptive Biotechnologies investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Adaptive Biotechnologies specific information freely available to individual and institutional investors to make a timely investment decision.
10th of January 2022
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
View
3rd of November 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
View
4th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
14th of June 2021
Submission of Matters to a Vote of Security Holders
View
5th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Adaptive Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.73 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Adaptive Biotechnologies's market, we take the total number of its shares issued and multiply it by Adaptive Biotechnologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Adaptive Profitablity

Adaptive Biotechnologies' profitability indicators refer to fundamental financial ratios that showcase Adaptive Biotechnologies' ability to generate income relative to its revenue or operating costs. If, let's say, Adaptive Biotechnologies is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Adaptive Biotechnologies' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Adaptive Biotechnologies' profitability requires more research than a typical breakdown of Adaptive Biotechnologies' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (129.89) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (130.7) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -1.31.
Last ReportedProjected for 2022
Return on Investment 16.67  17.98 
Return on Average Assets(0.13) (0.14) 
Return on Average Equity(0.20) (0.22) 
Return on Invested Capital(0.32) (0.35) 
Return on Sales(1.34) (1.44) 

Management Efficiency

The entity has return on total asset (ROA) of (11.47) % which means that it has lost $11.47 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (26.71) %, meaning that it created substantial loss on money invested by shareholders. Adaptive Biotechnologies management efficiency ratios could be used to measure how well adaptive biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to gain to 17.98 in 2022, whereas Return on Average Assets are likely to drop (0.14)  in 2022. Adaptive Biotechnologies Total Liabilities is comparatively stable at the moment as compared to the past year. Adaptive Biotechnologies reported Total Liabilities of 429.12 Million in 2021. Liabilities Non Current is likely to gain to about 332.5 M in 2022, whereas Current Liabilities is likely to drop slightly above 96.6 M in 2022.
Last ReportedProjected for 2022
Book Value per Share 6.51  7.03 
Enterprise Value over EBIT(59.80) (64.52) 
Enterprise Value over EBITDA(65.28) (70.44) 
Price to Book Value 12.51  11.62 
Tangible Assets Book Value per Share 6.77  9.18 
Enterprise Value8.8 B7.9 B
Tangible Asset Value1.1 B915.5 M

Technical Drivers

As of the 17th of January 2022, Adaptive Biotechnologies shows the risk adjusted performance of (0.13), and Mean Deviation of 3.27. Adaptive Biotechnologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Adaptive Biotechnologies Corp, which can be compared to its rivals. Please confirm Adaptive Biotechnologies coefficient of variation, as well as the relationship between the treynor ratio and semi variance to decide if Adaptive Biotechnologies is priced correctly, providing market reflects its regular price of 19.35 per share. Given that Adaptive Biotechnologies has jensen alpha of (0.81), we suggest you to validate Adaptive Biotechnologies Corp's prevailing market performance to make sure the company can sustain itself at a future point.

Adaptive Biotechnologies Price Movement Analysis

The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Adaptive Biotechnologies middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Adaptive Biotechnologies. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Adaptive Biotechnologies Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Adaptive Biotechnologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Adaptive Biotechnologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Adaptive Biotechnologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adams R Mark six days ago via Macroaxis 
Sale by Adams R Mark of 1021 shares of Adaptive Biotechnologies
Taylor Stacy L over three weeks ago via Macroaxis 
Exercise or conversion by Taylor Stacy L of 5208 shares of Adaptive Biotechnologies subject to Rule 16b-3
Harlan Robins over a month ago via Macroaxis 
Exercise or conversion by Harlan Robins of 300 shares of Adaptive Biotechnologies subject to Rule 16b-3
Harlan Robins over a month ago via Macroaxis 
Exercise or conversion by Harlan Robins of 300 shares of Adaptive Biotechnologies subject to Rule 16b-3
Piskel Kyle over two months ago via Macroaxis 
Acquisition by Piskel Kyle of 9592 shares of Adaptive Biotechnologies subject to Rule 16b-3
Cohen Chad M over two months ago via Macroaxis 
Exercise or conversion by Cohen Chad M of 5000 shares of Adaptive Biotechnologies subject to Rule 16b-3
Piskel Kyle over two months ago via Macroaxis 
Adaptive Biotechnologies exotic insider transaction detected
Harlan Robins over two months ago via Macroaxis 
Exercise or conversion by Harlan Robins of 3700 shares of Adaptive Biotechnologies subject to Rule 16b-3
Adams R Mark over three months ago via Macroaxis 
Sale by Adams R Mark of 1801 shares of Adaptive Biotechnologies
Cohen Chad M over three months ago via Macroaxis 
Exercise or conversion by Cohen Chad M of 5000 shares of Adaptive Biotechnologies subject to Rule 16b-3
Cohen Chad M over three months ago via Macroaxis 
Exercise or conversion by Cohen Chad M of 5000 shares of Adaptive Biotechnologies subject to Rule 16b-3
Harlan Robins over three months ago via Macroaxis 
Sale by Harlan Robins of 2795 shares of Adaptive Biotechnologies

Adaptive Biotechnologies Technical and Predictive Indicators

Adaptive Biotechnologies Forecast Models

Adaptive Biotechnologies time-series forecasting models is one of many Adaptive Biotechnologies' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Adaptive Biotechnologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Adaptive Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Adaptive Biotechnologies stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Adaptive shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Adaptive Biotechnologies. By using and applying Adaptive Stock analysis, traders can create a robust methodology for identifying Adaptive entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 8.68  9.36 
EBITDA Margin(1.23) (1.33) 
Gross Margin 0.89  0.87 
Profit Margin(1.34) (1.44) 
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. Adaptive Biotechnologies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 622 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Adaptive Biotechnologies to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run My Watchlist Analysis Now

   

My Watchlist Analysis

Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
All  Next Launch Module
Please continue to Trending Equities. Note that the Adaptive Biotechnologies information on this page should be used as a complementary analysis to other Adaptive Biotechnologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Adaptive Stock analysis

When running Adaptive Biotechnologies price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine Adaptive Biotechnologies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.